HOME >> MEDICINE >> NEWS
The CIS of New York receives grant to increase minority access to cancer information on the Web

NEW YORK, November 28, 2000 -- The Cancer Information Service (CIS) of New York, which is based at Memorial Sloan-Kettering Cancer Center, was recently awarded one of four grants totaling $932,000 from the National Cancer Institute (NCI) to improve awareness of and access to Internet-based cancer information in minority communities throughout the country. The CIS of New York will use the grant to implement the Bridging the Digital Divide Project: Your Access to Cancer Information in the Harlem community.

"What is really exciting about this project is that it brings together a host of new community partners to provide cancer information through the Internet. Together, we hope to address the problem called the Digital Divide," said Rosemarie Slevin Perocchia, Director of the Cancer Information Service of New York.

The Digital Divide -- the gap between those who have and those who do not have access to computer technology and the information provided through the Internet -- is considered a significant and growing problem worldwide, especially in the field of health-care.

Research shows that, while knowledge is not a guarantee of good health behavior, it contributes to good health-care decisions and behavior. According to the NCI, at least 50 million Americans -- about 20 percent of the country -- are faced with one or more barriers that prevent them from accessing cancer information on the Internet. These barriers include access to computers, education and literacy.

The Bridging the Digital Divide Project is a unique partnership, which will combine the CIS's expertise on cancer information resources with a diverse group of Harlem community organizations who offer Internet access to residents. The project will provide local residents with instruction on how to utilize on-line resources to learn more about cancer. The community organizations, chosen both because of their commitment to serve the Harlem community and their current compu
'"/>

Contact: Kate Monroe
monroek@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
27-Nov-2000


Page: 1 2

Related medicine news :

1. UIC professor receives international humanitarian award
2. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
3. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
4. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
5. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
6. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program
7. American Academy of Neurology program receives Grassroots Award
8. Orqis receives FDA approval to expand clinical trial of Cancion CRS therapy to 40 centers
9. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI
10. Pfizers antifungal medicine VFEND receives FDA approval
11. Shire receives US FDA approval of EQUETRO (TM) for bipolar disorder

Post Your Comments:
(Date:8/31/2015)... ... August 31, 2015 , ... For 12 years, since 2004, the ... 26th as Mesothelioma Awareness Day . On this day, and in the weeks ... of becoming involved and helping the cause. , “One of the ways a person ...
(Date:8/31/2015)... ... August 31, 2015 , ... Chicago-based company The Mood ... to raise money and awareness for breast and ovarian health. During September ... incandescent Mood-lite sold to Bright Pink® to encourage households, dorms, and offices around ...
(Date:8/31/2015)... ... 31, 2015 , ... The Brooks Group, a global sales ... department devoted to helping organizations identify and keep the best talent both inside ... Brooks Group believes in offering a solution that goes beyond simply providing assessments ...
(Date:8/31/2015)... ... August 31, 2015 , ... ERT, a leading global provider ... solutions will demonstrate multiple prototypes from its Innovation Lab during its 8th Annual ... the only European event dedicated to providing case studies and pragmatic information on ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... certifies products for the water, food, health sciences and consumer goods industries, has ... for their advanced iron filtration media, Pro-OX Manganese Dioxide. , Developed by a ...
Breaking Medicine News(10 mins):Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 2Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 3Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 2Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 3Health News:The Brooks Group Introduces Talent Management Division 2Health News:The Brooks Group Introduces Talent Management Division 3Health News:ERT to Demonstrate Innovation Lab Prototypes at European PRO / eCOA Congress 2Health News:ERT to Demonstrate Innovation Lab Prototypes at European PRO / eCOA Congress 3Health News:NSF International Has Recognized Clean Water Systems & Stores Inc Facility 2Health News:NSF International Has Recognized Clean Water Systems & Stores Inc Facility 3
(Date:8/31/2015)... PRINCETON, N.J. , Aug. 31, 2015  /PRNewswire/ ... Company), a late-stage biopharmaceutical company developing products that ... inflammation, oncology and biodefense, announced today it has ... by the Data Review Committee (DRC) earlier this ... SGX942.  SGX942 is a first-in-class innate defense regulator ...
(Date:8/31/2015)... , Aug. 31, 2015  Asterias Biotherapeutics, ... on the emerging field of regenerative medicine, today ... at Chicago -based Rush University ... evaluating activity of escalating doses of AST-OPC1 (oligodendrocyte ... and motor complete cervical spinal cord injury (SCI). ...
(Date:8/31/2015)... and STAMFORD, Conn. , Aug. ... of Eisai Co., Ltd., and Purdue Pharma L.P. announced ... agreement for the development and commercialization of Eisai,s clinical ... antagonist entering Phase III clinical development for the treatment ... the agreement, Eisai and Purdue Pharma will share the ...
Breaking Medicine Technology:Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5
Cached News: